FDA approves first ever treatment for neurofibromatosis – EurekAlert

CTF logo
CREDIT: Children’s Tumor Foundation


The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA’s approval of AstraZeneca’s and MSD (Merck)’s submission is a major milestone for patients living with neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the body. Affecting 1 in 3,000 people of all populations equally, this announcement is the first ever approved treatment for NF, and portends the potential for the development of treatment options for all NF patients.

Click here to read full article https://www.eurekalert.org/pub_releases/2020-04/ctf-faf041320.php

Font Resize